Form 4: Anika Therapeutics Director Gary P. Fischetti Reports Stock Transactions
SEC Form 4
Director Gary P. Fischetti of Anika Therapeutics reports acquisition and disposal of common stock and restricted stock units.
Summary
- On July 9, 2024, Gary P. Fischetti, a director of Anika Therapeutics, Inc., reported acquiring 5,771 shares of common stock and disposing of 27,449 shares.
- The acquisition of 5,771 shares was related to restricted stock units (RSUs).
- Each RSU represents the contingent right to receive one share of the company's common stock.
- The RSUs vest in full on the earlier of the 2025 annual meeting of the company's stockholders or July 9, 2025.
- Following these transactions, Fischetti beneficially owns 27,449 shares of Anika Therapeutics.
Sentiment
Score: 5
Explanation: The document is a standard regulatory filing detailing stock transactions by a company director, with no inherent positive or negative sentiment.
Future Outlook
The RSUs vest in full on the earlier of the 2025 annual meeting of the Company's stockholders or July 9, 2025.
Industry Context
This Form 4 filing is a routine disclosure related to insider transactions, providing transparency to investors regarding the trading activities of company directors.
Stakeholder Impact
- The disclosure of stock transactions by a director provides transparency to shareholders.
Key Dates
| Date | Description |
|---|---|
| 07/09/2024 | Date of stock acquisition and disposal. |
| 07/09/2025 | Date of RSU vesting (or earlier at the 2025 annual meeting). |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.